Clinical trials: Chemotherapy
Sleep Initiation and Maintenance Disorders
Efficacy of Ramelteon in Subjects With Chronic Insomnia
The purpose of this study is to determine the long-term safety of Ramelteon, once daily (QD), in subjects with chronic insomnia.
- Trial name
- NCT00671086
- Testing
- Ramelteon
- Where
- 122 sites in United States
- Volunteers
- 1,213 people
- Sponsor
- Takeda
Non-Small Cell Lung Cancer
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned.
- Trial name
- NCT06465329
- Testing
- Cemiplimab, Platinum-based chemotherapy, REGN7075
- Where
- 47 sites in United States, Brazil and 4 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Non-Small Cell Lung Cancer
A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%-85% of lung cancers cases. Squamous carcinoma accounts for 20-30% of all NSCLC cases.
- Trial name
- NCT07756645
- Testing
- ABBV-1480, Pembrolizumab, Carboplatin
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 940 people
- Sponsor
- AbbVie
Non-small Cell Lung Cancer (NSCLC)
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with carboplatin and paclitaxel in the treatment of chemonaive subjects with recurrent or advanced non-squamous NSCLC
- Trial name
- NCT00850577
- Testing
- Paclitaxel, Carboplatin, CT-322
- Where
- 55 sites in United States, Brazil and 6 more
- Volunteers
- 255 people
- Sponsor
- Bristol-Myers Squibb
Anemia
A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy
This study will evaluate the efficacy and safety of subcutaneous (SC) epoetin beta in anemic participants with breast cancer undergoing chemotherapy.
- Trial name
- NCT02761642
- Testing
- Epoetin Beta
- Where
- 27 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Hoffmann-La Roche
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy
The purpose of this study is to determine the maximum dose that is safely tolerated of the experimental drug Rhenium Re 188 P2045.
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Neoplasm Recurrence, Local
- Trial name
- NCT00100256
- Testing
- Rhenium (Re 188 P2045, BAY86-5284)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Andarix Pharmaceuticals
Ovarian Cancer
EP0057 in Combination With Olaparib in Advanced Ovarian Cancer
EP0057-201 is a Phase 2A/B adaptive design study. Phase 2A will test EP0057 in combination with Olaparib and Phase 2B, the randomised part of the study, will test EP0057 in combination with Olaparib against SOC chemotherapy.
- Trial name
- NCT04669002
- Testing
- EP0057, Olaparib tablets
- Where
- 21 sites in United States, Hungary and 1 more
- Volunteers
- 34 people
- Sponsor
- Ellipses Pharma
Advanced Primary Liver Cancer
Clinical Trial of Elemene in Combination With Oxaliplatinin the Treatment of Advanced Primary Liver Cancer
Clinical Trial of Elemene Injection/Elemene Oral Emulsion in Combination with Systematic Chemotherapy including Oxaliplatin in the First -line treatment of advanced primary liver cancer
- Trial name
- NCT03166553
- Testing
- Elemene
- Where
- 10 sites in China
- Volunteers
- 150 people
- Sponsor
- BeiJing Yijiayi Medicine Techonoloy Co., Ltd.
Ovarian Cancer
Clinical Trial for Ovarian Cancer (OvaRex®)
This study will compare the time to disease relapse between OvaRex® MAb-B43.13-treated patients and placebo-treated patients. This study will also compare assessments of survival, quality of life, immune response and safety…
- Trial name
- NCT00050375
- Testing
- oregovomab
- Where
- 62 sites in United States
- Volunteers
- 354 people
- Sponsor
- Unither Pharmaceuticals
Small Cell Lung Carcinoma
RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer
This is a study to investigate the potential clinical benefit of roniciclib when given in combination with chemotherapy Carboplatin / Etoposide or Cisplatin / Etoposide as first line treatment in patients with extensive disease…
- Trial name
- CONCEPT-SCLC (NCT02161419)
- Testing
- Roniciclib (BAY1000394)
- Where
- 32 sites in United States, Belgium and 7 more
- Volunteers
- 142 people
- Sponsor
- Bayer
Depression, Anxiety
Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm
Antidepressants are among the most widely prescribed medications, yet only 35-45% of patients achieve remission following an initial antidepressant trial.
- Trial name
- UHS (NCT01632267)
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Assurex Health Inc.
Leukemia, Myeloid, Acute
A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
The purpose of this study is to define the maximum tolerated dose (MTD) of AC220 when combined with induction and consolidation therapy and as maintenance therapy following induction and consolidation.
- Trial name
- NCT01390337
- Testing
- AC220, daunorubicin, cytarabine
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Daiichi Sankyo
Ovarian, Primary Peritoneal
Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This is a multiregional, multicenter, randomized, open-label, phase III study to compare the efficacy, safety, and tolerability of IBI354 monotherapy with investigator's choice of chemotherapy (paclitaxel, gemcitabine, liposomal…
- Conditions
- Ovarian, Primary Peritoneal, Fallopian Tube Cancer
- Trial name
- NCT06834672
- Testing
- IBI354, paclitaxel/Gemcitabine/Liposomal doxorubicin
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
HIV Infections
A Study of Ritonavir (ABT-538) When Used With Nelfinavir in HIV-Infected Patients
The purpose of this study is to see if it is safe and effective to give ritonavir plus nelfinavir to HIV-infected patients. This study will also see how ritonavir and nelfinavir are absorbed by the body and how they affect the…
- Trial name
- NCT00002201
- Testing
- Ritonavir, Nelfinavir mesylate
- Where
- United States
- Sponsor
- Abbott
Crohn's Disease
Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease
The purpose of this study is to evaluate the percentage of participants with perianal fistula healing at Week 30 in 2 different dose regimens of vedolizumab intravenous (IV) 300 milligram (mg) in participants with fistulizing…
- Trial name
- ENTERPRISE (NCT02630966)
- Testing
- Vedolizumab
- Where
- 18 sites in United States, Canada and 5 more
- Volunteers
- 34 people
- Sponsor
- Takeda
Prostatic Neoplasms, Castration-Resistant
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
The overall aim of the trial is to investigate the safety and anti-tumour activity of an experimental drug BI 836845 taken together with the prostate cancer drug, enzalutamide, compared to enzalutamide given alone, in castrate…
- Trial name
- NCT02204072
- Testing
- BI 836845, Enzalutamide
- Where
- 27 sites in United States, Hong Kong and 6 more
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
Moderately to Severely Active Ulcerative Colitis
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis
The purpose of this study is to assess the effect of vedolizumab intravenous IV as induction and maintenance treatment in Chinese participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- NCT03221036
- Testing
- Vedolizumab IV
- Where
- 36 sites in China
- Volunteers
- 392 people
- Sponsor
- Takeda
Cancer of Unknown Primary Site
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with poor-prognosis cancer of unknown primary site (CUP; non-specific subset) who have…
- Trial name
- CUPISCO (NCT03498521)
- Testing
- Alectinib, Vismodegib, Ipatasertib
- Where
- 125 sites in Australia, Austria and 31 more
- Volunteers
- 529 people
- Sponsor
- Hoffmann-La Roche
Lung Neoplasms
A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy
The purpose of this study is to determine whether CP-547,632, an oral VEGFR-2 tyrosine kinase inhibitor when given in combination with chemotherapy (carboplatin and paclitaxel) is effective in the treatment of advanced stage…
- Trial name
- NCT00074854
- Testing
- CP-547,632
- Where
- 20 sites in United States
- Volunteers
- 87 people
- Sponsor
- Pfizer
Hodgkin Disease
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
The purpose of this study is to assess safety and efficacy of brentuximab vedotin in combination with bendamustine in patients with relapsed or refractory Hodgkin lymphoma.
- Trial name
- NCT01874054
- Testing
- brentuximab vedotin, bendamustine
- Where
- 13 sites in United States
- Volunteers
- 55 people
- Sponsor
- Seagen Inc.